HeartInsight, a remote heart failure (HF) management solution received CE Mark.
Biotronik announced the CE approval for HeartInsight, its remote heart failure (HF) management solution that accurately identifies patients at higher risk of HF decompensation early on.
HeartInsight predicts two out of three HF hospitalizations, coupled with an industry-low false alert rate. Compared to other available solutions, HeartInsight provides the earliest notification, a median advance notice of 42 days before an impending HF hospitalization, which allows clinicians to proactively care for their patients. HeartInsight will be presented to clinicians for the first time at the EHRA Congress which takes place in Copenhagen, Denmark, from April 3 to 5, 2022.
HeartInsight will be available for patients with compatible CRT-D and ICD devices and is integrated into Biotronik’s Home Monitoring platform which displays patient health data that is transmitted from their cardiac implant automatically every day. HeartInsight’s algorithm combines relevant HF parameters into one predictive score and alerts the clinical team that a patient is at higher risk of hospitalization once a pre-set threshold has been crossed. All relevant information is organized in an insightful dashboard, designed for improved collaboration and decision-making.
Related news and insights
The Menarini Group and Radius Health, Inc. announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the FDA for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announce positive results of the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia (NCT03548584).